Delivery Order SPE2DB24D3014-SPE2DB25FKTYS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,279.87 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (30-count package) on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and healthcare systems. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,522.97 to AmerisourceBergen Drug Corp for 90 tablets of Gemtesa 75 mg, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order, awarded on July 25, 2025, represents a non-set-aside competitive award for pharmaceutical supply to support federal medical procurement needs. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $48,927.46 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on April 23, 2025, with an ultimate completion date of April 24, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count units) valued at $7,179.96. This firm fixed-price, non-set-aside contract was awarded on July 31, 2025, with an ultimate completion date of August 1, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a delivery order, this award represents a single fulfillment action under a larger contracting vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,792.03 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on July 23, 2025, with completion scheduled for July 24, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical supply vehicle running through...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,425.51 to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a $7,642.01 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count package) with completion targeted for September 10, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a $12,673.62 delivery order to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on May 30, 2025, with an ultimate completion date of June 2, 2025. This firm fixed-price contract, which involves no set-aside designation, represents a competitively awarded delivery order under the company's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, on July 29, 2025. The contract, valued at approximately $12.1K, is for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price arrangement. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on September 24, 2025, with a ceiling value of $15,126.73. This is a firm fixed-price delivery order with no set-aside designation, executed competitively against the vendor's larger indefinite delivery contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 25, 2025. This...
- SPE2DB24D3014Indefinite Delivery Contract
- SPE2DB24D3014-SPE2DB25FKTYSDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,640.77 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on July 11, 2025, with an ultimate completion date of July 14, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply relationship with the federal government, specifically supporting military and veteran healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen fulfills critical medical procurement needs through the DLA Medical Supply Chain, supplying brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains. The award reflects the company's established capability to meet federal procurement requirements through open competition and its role as a key vendor in the Defense Health Agency's pharmaceutical supply infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.6k | 7/11/25 |